Author

S. Paithankar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Chen· 3 shared C. Lawson· 2 shared J. Prokop· 2 shared K. Tripp· 2 shared K. Uhl· 2 shared M. Abdelgied· 2 shared R. R. Neubig· 2 shared X. Li· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

B. Chen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Bulk RNA-Sequencing of small airway cell cultures from IPF and post-COVID lung fibrosis patients illustrates disease signatures and differential responses to TGF-β1 treatment

K. Uhl, S. Paithankar, D. Leshchiner, T. Jager, M. Abdelgied, K. Tripp, A. Peraino, M. Kakazu, C. Lawson, D. Chesla, J. Prokop, B. Chen, E. Murphy, R. Girgis, X. Li

This study uses bulk RNA-sequencing to compare gene expression in small airway cells from IPF and post-COVID fibrosis patients, revealing disease-specific genetic signatures and differential responses to TGF-β1 treatment.

bioRxiv · Mar 1, 2023 · PreprintCell Biology

Targeting ATP12A, a non-gastric proton pump alpha subunit, for idiopathic pulmonary fibrosis treatment

M. Abdelgied, K. Uhl, O. G. Chen, C. Schultz, K. Tripp, A. M. Peraino, S. Paithankar, B. Chen, M. T. Kakazu, A. C. Bahena, T. E. Jager, C. Lawson, D. W. Chesla, N. Pestov, N. N. Modyanov, , X. Li

This study identifies ATP12A as a potential therapeutic target for idiopathic pulmonary fibrosis by showing its overexpression in IPF lungs and its role in worsening fibrosis in mice.

bioRxiv · Jun 8, 2022Cell Biology

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells

S. A. Misek, P. A. Newbury, E. Chekalin, S. Paithankar, A. I. Doseff, B. Chen, K. A. Gallo, R. R. Neubig

This study identifies ibrutinib as a drug that reverses BRAFi resistance in melanoma by inhibiting YAP1 and acting through SRC kinase off-target effects, not BTK.

bioRxiv · Mar 25, 2020Cancer Biology